Trial results

Efficacy and Safety of Tirzepatide for Weight Management

NCT06918405 on ClinicalTrials.gov · last registry update 2025-04-09

Closed to new participants; the 440 already enrolled are still being followed. Its estimated completion date, 30 June 2026, has passed with no update to the record. Primary outcome, as filed: Change in body weight (kg). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Chittagong Medical College

Sponsor type

Other

Enrollment

440

Started

2025-01-01

Primary completion

2026-06-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in body weight (kg)

Conditions studied

Obesity and Obesity-related Medical Conditions

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.